Confluence Investment Management LLC boosted its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 2.7% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 81,655 shares of the medical instruments supplier’s stock after buying an additional 2,181 shares during the period. Confluence Investment Management LLC’s holdings in Becton, Dickinson and were worth $15,932,000 at the end of the most recent quarter.
Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Crestwood Advisors Group LLC purchased a new position in Becton, Dickinson and during the first quarter worth $101,000. North Star Investment Management Corp. boosted its position in Becton, Dickinson and by 3.4% in the first quarter. North Star Investment Management Corp. now owns 549 shares of the medical instruments supplier’s stock worth $101,000 after buying an additional 18 shares during the period. Almanack Investment Partners LLC. purchased a new position in Becton, Dickinson and during the first quarter worth $105,000. Parkside Financial Bank & Trust boosted its position in Becton, Dickinson and by 1.4% in the first quarter. Parkside Financial Bank & Trust now owns 633 shares of the medical instruments supplier’s stock worth $116,000 after buying an additional 9 shares during the period. Finally, Financial Architects Inc boosted its position in Becton, Dickinson and by 62.7% in the first quarter. Financial Architects Inc now owns 677 shares of the medical instruments supplier’s stock worth $124,000 after buying an additional 261 shares during the period. Institutional investors own 75.57% of the company’s stock.
Shares of Becton, Dickinson and Company (BDX) traded up 0.36% during mid-day trading on Friday, hitting $198.57. 789,306 shares of the stock traded hands. Becton, Dickinson and Company has a 12 month low of $161.29 and a 12 month high of $206.63. The firm has a 50 day moving average of $200.05 and a 200 day moving average of $189.42. The company has a market cap of $45.19 billion, a P/E ratio of 57.51 and a beta of 1.05.
Becton, Dickinson and (NYSE:BDX) last released its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a net margin of 6.25% and a return on equity of 22.53%. The company had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. During the same period last year, the company earned $2.35 EPS. The firm’s revenue for the quarter was down 5.1% compared to the same quarter last year. Equities analysts anticipate that Becton, Dickinson and Company will post $9.46 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 29th. Shareholders of record on Friday, September 8th will be paid a dividend of $0.73 per share. The ex-dividend date is Thursday, September 7th. This represents a $2.92 annualized dividend and a dividend yield of 1.47%. Becton, Dickinson and’s dividend payout ratio is currently 83.43%.
ILLEGAL ACTIVITY NOTICE: This report was posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are accessing this report on another site, it was copied illegally and reposted in violation of international trademark and copyright law. The correct version of this report can be read at https://stocknewstimes.com/2017/08/27/confluence-investment-management-llc-has-15-93-million-position-in-becton-dickinson-and-company-bdx.html.
A number of research analysts recently weighed in on the stock. BidaskClub upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating in a research note on Monday, August 14th. Cowen and Company restated an “outperform” rating and set a $230.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research note on Monday, July 10th. Barclays PLC restated an “equal weight” rating and set a $210.00 target price (up previously from $205.00) on shares of Becton, Dickinson and in a research note on Thursday, August 10th. Zacks Investment Research upgraded shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price on the stock in a research note on Monday, July 17th. Finally, Raymond James Financial, Inc. upgraded shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and decreased their price target for the stock from $210.00 to $180.00 in a research note on Friday, June 30th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $195.79.
In other Becton, Dickinson and news, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction dated Wednesday, August 9th. The shares were sold at an average price of $197.41, for a total transaction of $1,178,735.11. Following the sale, the insider now directly owns 12,861 shares of the company’s stock, valued at approximately $2,538,890.01. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Ellen R. Strahlman sold 9,283 shares of the firm’s stock in a transaction dated Thursday, August 10th. The stock was sold at an average price of $198.21, for a total transaction of $1,839,983.43. Following the sale, the insider now directly owns 26,638 shares in the company, valued at $5,279,917.98. The disclosure for this sale can be found here. Insiders have sold a total of 48,605 shares of company stock worth $9,718,986 over the last ninety days. 1.40% of the stock is owned by corporate insiders.
About Becton, Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
